Updated ELVN-001 results showed strong molecular response rates in previously treated CML patients, while the FDA aligned with the company on key elements of its planned Phase 3 study.
Key Investor Takeaways
- Enliven Therapeutics (NASDAQ:ELVN) reported updated positive Phase 1 data for ELVN-001 in chronic myeloid leukemia (CML).
- The FDA aligned with the company on the Phase 3 dose and patient population for the planned ENABLE-2 pivotal trial.
- The 80 mg once-daily cohort delivered a 61% overall major molecular response (MMR) rate and a 48% MMR achievement rate by 24 weeks.
- Safety data remained favorable, with only 6% of patients discontinuing treatment due to adverse events.
- Phase 3 initiation is expected in the second half of 2026, creating a significant upcoming catalyst for ELVN stock.
Why ELVN Stock Is In Focus
Enliven Therapeutics announced updated clinical results from its ongoing Phase 1 ENABLE study evaluating ELVN-001 in patients with previously treated chronic myeloid leukemia.
Among patients receiving the selected 80 mg once-daily dose in Phase 1b, the trial produced a 61% overall major molecular response (MMR) rate, with 48% of evaluable patients achieving MMR within 24 weeks. Deep molecular response rates reached 30% in this cohort.
The company also reported encouraging outcomes among patients who had received one or two prior tyrosine kinase inhibitors (TKIs). In that group, overall MMR reached 67%, while 55% achieved MMR by 24 weeks.
Importantly, Enliven disclosed that the FDA has aligned with the company on using the 80 mg once-daily regimen as the recommended Phase 3 dose. The agency also agreed on enrolling patients who have previously received at least one TKI in the planned ENABLE-2 Phase 3 trial.
The pivotal study is expected to begin during the second half of 2026.
Why This Matters for Investors
For clinical-stage biotechnology companies, regulatory alignment and late-stage development progress are often major value-driving events.
The FDA’s agreement on both dose selection and patient population may reduce development uncertainty as Enliven advances ELVN-001 toward its pivotal trial. Regulatory clarity can be particularly important because it helps establish a defined pathway toward potential approval.
The updated efficacy data may also strengthen the investment case for ELVN-001. The company reported meaningful molecular response rates across heavily pretreated patients, including individuals previously exposed to multiple therapies and patients who had received prior asciminib treatment.
Safety remains another important factor. According to the company, ELVN-001 demonstrated a favorable tolerability profile, with relatively low treatment discontinuation rates and fewer severe adverse events at the selected Phase 3 dose.
Together, the efficacy, safety, and regulatory updates suggest ELVN-001 is advancing toward a more critical stage of development, where investors will increasingly focus on Phase 3 execution and potential commercial positioning in the CML market.
What To Watch Next
Investors will likely monitor several upcoming milestones:
- Initiation of the Phase 3 ENABLE-2 trial in the second half of 2026.
- Additional discussions with the FDA regarding final Phase 3 study design.
- The planned End-of-Phase 2 meeting expected in the third quarter of 2026.
- Further efficacy and safety updates from the ongoing ENABLE study.
- Enrollment progress and execution of the pivotal Phase 3 program.
The launch of ENABLE-2 represents the next major catalyst as Enliven seeks to move ELVN-001 from early-stage development into a registrational study.